1.
|
Phase: Phase IV
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA180-400, 2011-006180-21, NCT01660906
|
|
2.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 4443, 2007-006185-15, ISRCTN54923521, NCT01460693
|
|
3.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2006-0900, NCT00566618
|
|
4.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 90
Sponsor: Other
Protocol IDs: 08-122, NCT00820170
|
|
5.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SCLL084993, NCT00829647
|
|
6.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCCTG-N0877, N0877, NCT00869401
|
|
7.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 90
Sponsor: Other
Protocol IDs: J08101, CA180123, NCT00882583
|
|
8.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: ALSSMBC0804, NCT00924352
|
|
9.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA180-323, 2010-019480-11, NCT01218477
|
|
10.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: GEICAM/2010-04, NCT01306942
|
|
11.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: 2011-0254, NCT01460498
|
|
12.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2011-0333, CA180357, NCT01498445
|
|
13.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PRI-724-201, NCT01606579
|
|
14.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 2011-203, NCT01609816
|
|
15.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 2011-204, NCT01643603
|
|
16.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 70 and under
Sponsor: NCI, Other
Protocol IDs: 1581.00, NCI-2010-00131, P01CA078902, P01CA018029, FHCRC-1581.00, 5235, NCI-H02-0087, NCT00036738
|
|
17.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2005-0422, NCT00254423
|
|
18.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00226, 07070, N01CM62207, CDR0000576527, OSU-07070, 7813, NCT00563290
|
|
19.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: ECOG-E2607, E2607, NCT00700882
|
|
20.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA180-185, USOR 06-185, NCT00696072
|
|
21.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 1 to 21
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA180-226, 2008-002260-33, NCT00777036
|
|
22.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 60
Sponsor: NCI
Protocol IDs: SWOG-S0805, S0805, NCT00792948
|
|
23.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Pro00008303, NCT00787267
|
|
24.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCCTG-N0872, N0872, NCT00892177
|
|
25.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 0809009979, NCT00918463
|
Mobile | Español
